Drug intelligence / Profile preview

dPD-1 (TSHR+CD19) CAR-T cells

Development stage: Unknown
Lead developer: The Third Affiliated Hospital of Sun Yat-sen University
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

dPD-1 (TSHR+CD19) CAR-T cells are an autologous chimeric antigen receptor (CAR) T-cell therapy designed to target thyroid-stimulating hormone receptor (TSHR) and CD19. Developed by the Third Affiliated Hospital of Sun Yat-sen University, this cell therapy is specifically investigated for the treatment of refractory or relapsed thyroid cancer. The construct incorporates a dominant-negative PD-1 (dPD-1) modification, which is intended to shield the CAR-T cells from PD-1/PD-L1 mediated immunosuppression within the tumor microenvironment, thereby enhancing their anti-tumor activity and persistence. The dual-targeting approach and the checkpoint blockade integration represent a strategy to improve efficacy in solid tumors like thyroid carcinoma.

Other names: dPD-1(TSHR+CD19) CART Cell

Targets

TSHR (Thyroid-stimulating hormone receptor)CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on dPD-1 (TSHR+CD19) CAR-T cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dPD-1 (TSHR+CD19) CAR-T cells.

Explore the full profile